1. Introduction {#sec0005}
===============

Ischemic stroke is the second leading cause of death which poses an ever-increasing challenge around the world, and is associated with sociocultural and lifestyle changes ([@bib0040]).

Pharmacologic studies have introduced many novel therapeutic agents that have enhanced the recovery of stroke and other diseases ([@bib0105]; [@bib0055], [@bib0060]). Several treatment options such as thrombolysis have been identified for stroke. Adverse side effects of these approaches make them limited. Therefore, new therapeutic agents or approaches are required to increase life expectancy in patients with stroke. During stroke and neurodegenerative diseases, different signaling pathways are involved in cell fate ([@bib0130]; [@bib0005]; [@bib0135]). Targeting these signaling pathways by therapeutic agent postpones neuronal death in the brain after cerebral ischemia. Berberine is a yellow plant isoquinoline alkaloid isolated from herb medicine Coptidis Rhizom, Hydrastis canadensis, and berberis that plays an important role in neuroprotection against pro-inflammatory responses and escape from apoptotic signals ([@bib0140]). A large number of pharmacological and biological properties of berberine have been identified including anti carcinogenic ([@bib0115]), anti-inflammatory ([@bib0045]; [@bib0180]), anti-microbial ([@bib0175]), antihypertensive ([@bib0145]) and cholesterol lowering effects ([@bib0170]).

Existing researches have shown that berberine can ameliorate ischemia/reperfusion injury through several mechanisms:

One, berberine can up-regulate pAkt, pGSK and pCREB, and down-regulate NF-κB that resulted in cell survival in the acute phase of cerebral ischemia ([@bib0215]; [@bib0200]). Two, it can activate Akt and PI3K p55γ promoter which in turn reduces pro-apoptotic factors such as Bad and caspase-3 ([@bib0050]; [@bib0200]). Three, the anti-apoptotic effect of berberine is due to inhibition of AMPK pathway ([@bib0025]). Four, berberine inhibits apoptosis through downregulation of Bax, caspase 3, caspase 8, caspase 9 and subsequently induces autophagy in focal cerebral ischemia ([@bib0205]). Five, it activates JAK2/STAT3 signaling and inhibits endoplasmic reticulum stress ([@bib0220]). Likewise, current studies have shown anti-inflammatory effects of berberine against transient global cerebral ischemia in animal models ([@bib0155]). Berberine may confer neuroprotection against ischemia via modulation of potassium currents in CA1 pyramidal neurons of hippocampus in vitro model ([@bib0165]). Moreover, berberine helps to inhibit N-methyl-D-aspartate receptor 1 immunoactivity which in turn resulting in cell survival in CA1 hippocampus region after cerebral ischemia ([@bib0195]). Herein, we evaluate the effects of berberine on inflammation and inflammatory cytokines. Berberine might be used as a potential therapeutic agent to reduce inflammation and neuronal demise after ischemic stroke.

2. Materials and methods {#sec0010}
========================

2.1. Chemicals {#sec0015}
--------------

Berberine) B3251 SIGMA) chloral hydrate (C8383 SIGMA), paraformaldehyde (158127 SIGMA) and 2,3,5-triphenyltetrazolium chloride (T8877 SIGMA(were obtained from Sigma Chemical Co. Silicon rubber-coated monofilament for MCAO model was purchased from Doccol company (Philadelphia, PA, USA). Anti-IL10 antibody (ab34843), Anti-IL1 beta antibody (ab2105) and anti-TNFα (ab9635) were purchased from Abcam Company (Cambridge, UK). Goat anti-rabbit IgG-FITC Secondary Antibody was obtained from Santa Cruz Biotechnology\'s company.

2.2. Animals and ethical statement {#sec0020}
----------------------------------

Ten-week-old male Wistar rats (200--250 g) were purchased from animal laboratory of Iran University of Medical Sciences, and all experimental tests and the procedures were confirmed by the Institutional Animal Ethical Committee of Iran University of Medical Sciences. Rats were maintained under standard laboratory conditions (in a controlled temperature 25 ± 1 °C, with a 12-h dark: 12-h light cycle, 60% humidity, sterile water and food). The animals were randomly assigned into four groups: a control group of healthy rats (*n* = 20), sham-operated control group (sham, *n* = 20), only ischemia + saline (MCAO, *n* = 20), and treatment group (MCAO + Berberine, *n* = 20).

2.3. MCAO model {#sec0025}
---------------

The animals were anesthetized with 10% chloral hydrate (400 mg/kg body weight) by intraperitoneal injection. To make transit focal ischemia, MCAO model was used as described previously. In sum, a midline neck incision was made to isolate the right common carotid artery, external carotid artery and internal carotid artery. After occlusion of the common carotid artery by micro-clip, external carotid artery was clamped and a monofilament nylon suture was inserted from the right common carotid artery to the internal carotid artery by stumping external carotid artery and gradually moved until mild resistance was felt, confirming the middle cerebral artery occlusion. After 45-min ischemia, the monofilament was removed to allow recirculation of cerebral blood flow for 24 h and the skin incision was closed by surgical clips. During the whole surgery, body temperature of animals were monitored and maintained at 37 °C via measurement by a rectal probe. The same procedure was used for sham-operated control rats except filament insertion.

2.4. Neurobehavioral evaluation {#sec0030}
-------------------------------

Neurobehavioral assessments were performed 24 h after reperfusion by an observer blinded to the treatment groups. A six-point scale by Longa et al. was used to perform neurobehavioral assessments ([@bib0110]). 0, no deficits; 1, failure in fully extending the contralateral forelimb; 2, failure to extend the contralateral forelimb; 3, circling to the contralateral side; 4, falling to the left; 5, no spontaneously walking and exhibition of a depressed level of consciousness.

2.5. Anesthesia and tissue collection {#sec0035}
-------------------------------------

To examine histochemical analysis, the animals were finally anesthetized at the end of behavioral assessments and after decapitating animals, their brains were removed. Cortex regions of brain were dissected and maintained at --80 °C prior to immunohistochemical analysis.

2.6. Infarct volume determination {#sec0040}
---------------------------------

After the behavioral assessments, the animals were re-anesthetized and decapitated. The brains were quickly cooled in iced saline for 10 min, and then were cut by a brain matrix to several 2 mm thick coronal sections. The sections were incubated in TTC at 37 °C for 20 min, and then were fixed in 10% buffered formalin solution. A digital camera was used to take photograph of the slices. Infarct volume was identified as unstained regions and was calculated through an image analysis software.

2.7. Determination of brain water content {#sec0045}
-----------------------------------------

Brain water content was evaluated via wet/dry method in different groups (*n* = 4 for each group). In summary, rats were decapitated under an over dose mixture of ketamine and xylazine after 24 h reperfusion. The brains were divided into ischemic and contralateral hemispheres. Ischemic hemisphere was weighed (wet weight) then placed in an oven at 110 °C f for 24 h and again was weighed (dry weight). Brain water content was determined via (wet weight − dry weight)/wet weight \* 100%.

2.8. Immunohistochemistry {#sec0050}
-------------------------

Goat serum (10%) was used to block 5-micrometer sections from paraffin embedded brain tissue. Slices were incubated with primary antibody (1:100) (TNFα antibody, IL-1β and IL-10) at 1 μg/ml in 1% BSA/PBS for 1 h, followed by incubation with specific horseradish peroxidase-conjugated secondary antibody (1:150), each for 30 min. The sections were visualized with a microscope (Olympus, Japan). Quantification of immunohistochemical assay was based on fluorescence intensity.

2.9. Statistical analysis {#sec0055}
-------------------------

Values were expressed as means ± SD. Analysis was performed using Prism Software, version 5. Statistical difference between two groups was determined by two-tailed Student\'s *t* tests. Comparison of three or more groups was performed using One-way analysis of variance followed by LSD test for post hoc analysis. Values were considered statistically significant in *p* \< 0.05.

3. Results and discussion {#sec0060}
=========================

3.1. Neurological outcomes and infarct volume {#sec0065}
---------------------------------------------

Previous studies have shown that following transient focal cerebral ischemia oxidative stress and overexpression of pro-inflammatory cytokines cause neurologic deficits, brain edema and neuronal death ([@bib0090]; [@bib0190]; [@bib0150]). To evaluate neuroprotective effect of berberine, we first examined neurobehavioral function through behavioral assessment. Tianpei and coworker reported that berberine can ameliorate neurologic deficits and infarct volume in global ischemia ([@bib0185]). Our results show that there were no significant neurological deficits between control and sham groups. As shown in [Fig. 1](#fig0005){ref-type="fig"}, significant difference (*p* \< 0.01) was observed between the ischemia and treatment groups. Treatment group displayed a significant reduction in neurological deficits score compared to ischemia group (*n* = 8 for each group, *p* \< 0.01). Likewise, the results depicted in [Fig. 1](#fig0005){ref-type="fig"}B by ladder test display following 24 h after reperfusion; .Statistical significant differences were observed between control and ischemia cohorts (*n* = 8 for each group, *p* \< 0.001). Berberine administration significantly restores motor function than ischemia group (*p* \< 0.05).Fig. 1Berberine treatment improves neurological outcomes. (A) Post-treatment by berberine significantly decreases neurological deficits score (^\#^*p* \< 0.01 compared with ischemia group). (B) Neurological deficits were increased in ischemia group compared to control and sham groups (\**p* \< 0.001 compared to control and sham group). Ladder test displays recovery of treatment group compared to ischemia group (^\#^*p* \< 0.05 compared to ischemia group).Fig. 1

It has been identified that berberine can attenuate infarct volume in MCAO animal model ([@bib0230]). To examine infarct volume, the slices were immersed in a solution of 2% TTC, and after 20 min white areas were described as the infarcted brain tissue and red areas were defined as the non-infarcted region ([@bib0030]).

As shown in [Fig. 2](#fig0010){ref-type="fig"}a and b, no significant differences between control and ischemia group were observed by TTC staining. Berberine post treatment reduced infarction volumes. The infarct volume of the treatment group was 22% lower compared with ischemia group (*n* = 4 for each group, *p* \> 0.01).Fig. 2Berberine post-treatment reduced infarction volume in rats. (A) The sections were stained by immersing them in a solution of TTC and non-infarcted region appeared red, whereas the infarcted region appeared white. (B) Berberine administration significantly reduces total infarct volume (^\#^*p* \< 0.01 compared with ischemia group).Fig. 2

3.2. Brain water content {#sec0070}
------------------------

Brain edema plays an important role in the pathophysiology of neurologic deficits such as stroke and is a common sequel of post-injury inflammation and blood-brain barrier (BBB) breakdown ([@bib0120]). Cerebral water balance is hamper in cerebral ischemia ([@bib0210]). There is a close association between inflammation and brain edema. It seems that overexpression of interleukin-1 receptor antagonist can highly attenuate brain edema ([@bib0125]). Accumulative evidences have shown that berberine can contribute to normalization of cerebral water balance after brain injury via inhibition of Glia-mediated inflammation ([@bib0015]). To evaluate the anti-inflammatory effects of berberine, we measured brain water content in different groups. Following 24 h reperfusion, water content of the brain tissue for the control, sham, ischemia and treatment groups were77.35%, 78.83%, 80.63%, 77.89% respectively. Our results indicated a significant difference between sham and ischemia groups (*p* \< 0.01).

Water content of the brain increased significantly in ischemia group compared to control and sham group. Decreased water content observed in treatment group than ischemia group giving clear evidence that berberine alleviates brain edema formation following ischemic stroke ([Fig. 3](#fig0015){ref-type="fig"}).Fig. 3Berberine post-treatment decreased brain edema. Brain water contentsignificantly increased in MCAO compared to control group (\**p* \< 0.01). There was a statistical difference between MCAO and MCAO + Berberine groups, confirming anti-inflammatory effect of Berberine (^\#^*p* \< 0.001 compared with MCAO group).Fig. 3

3.3. Immunohistochemical analysis {#sec0075}
---------------------------------

Exiting researches have shown that berberine can contribute to neuroprotection in coping with oxidative stress and ischemic stroke through targeting different signaling pathways ([@bib0215]). In addition, this isoquinoline alkaloid can interact with mRNAs that lead to up-regulation of several proteins and escape of proapoptic signals ([@bib0010]). Berberine can inhibit proinflammatory responses via AMPK activation in macrophages ([@bib0065]). Recent studies have shown that berberine might downregulate proinflammatory cytokines in a AMPK-independent manner ([@bib0180]). Likewise, Berberine can suppress proinflammatory responses through downregulation of proinflammatory cytokines such as TNFα and IL-6 in AcLDL-stimulated macrophages via PPARγ signaling pathway ([@bib0020]; [@bib0160]). Moreover, Berberine may decrease inflammation by targeting MAPK pathway that in turn suppresses the expression of proinflammatory cytokines ([@bib0085]). Berberine inhibits cell invasion by supressing TNF-α-induced MMP-9 in human breast cancer ([@bib0070]).

In present work, immunohistochemical studies have shown that TNFα expression was signtificantly increased than control and sham groups (*p* \< 0.001). Berberine highly inhibited the expression of TNFα compared to MCAO cohorts ([Fig. 4](#fig0020){ref-type="fig"}A). Our results displayed berberine administration exhibited a significant anti-inflammatory effect on cerebral ischemia through supression of proinflammatory cytokines.Fig. 4(A) Berberine post-treatment decreased TNFα level. Immunohistochemical analysis results demonstrated that MCAO markedly increased the protein levels of TNFα compared with control and sham groups (\**p* \< 0.001 compared to control and sham groups). TNFα proinflammatory cytokine was significantly decreased compared to ischemia group (^\#^*p* \< 0.001). (B) MCAO induced a robust increase in IL-1β levels (\**p* \< 0.001 compared to control and sham groups). Berberine post-treatment decreased the level of IL-1β pro-inflammatory cytokine (^\#^*p* \< 0. 01 compared to MCAO group) (^\$^*p* \< 0. 01 compared to control and sham groups).Fig. 4

It has been recognized that berberine can decrease inflammatory agents-induced interleukin-1β and TNFα ensuing inflammation in human lung cells ([@bib0075]). Many emerging evidences have shown that berberine contributes to cell survival and inhibition of inflammation by downregulating IL-1β expression ([@bib0095], [@bib0100]). For example, berberine mediates inhibition of cartilage degeneration in IL-1β-stimulated rat chondrocytes through downregulation of IL-1β in a Akt-dependent fasion ([@bib0225]). Besides, following deactivation of JNK signaling pathways by berberine, lower levels of TNF-α and IL-1β have been observed in acute pancreatitis disease ([@bib0035]).

Likewise, in present work our finding indicates that IL-1β level signtificantly was increased in MCAO group than control animals (2200pikel/um2), indicating a potent detrimental effect of this proinflammatory cytokine in cerebral ischemia. Decreased level of IL-1β was found in treatment group (*p* \< 0.05).

On the other hand, berberine can increase the expression of anti-inflammatory cytokines. In work by Kim and coworker berberine not only decreases the expression of iNOS, COX-2, IL-1β, IL-6, and TNF-α, but also enhances IL-10 expression to inhibit lipid peroxidation in inflammatory bowel diseases ([@bib0080]). We examined the effects of berberine on anti-inflammatory cytokines.

We found that focal cerebral ischemia increased IL-10 expression (200pikel/um) compared to control animals (less of 100 pikel/um), whereas berberine dramatically elevated IL-10 levels more than both control and ischemia groups (270 pikel/um), again confirming potent anti-inflammatory effects of berberine ([Fig. 5](#fig0025){ref-type="fig"}).Fig. 5Following MCAO, IL-10 level was increased compared to control and sham groups. A robust increase in IL-10 anti-inflamatory cytokine was observed after treatment by berberine in cortex region (^\#^*p* \< 0.05 compared with MCAO group) (\**p* \< 0.001 compared to control and sham groups).Fig. 5

4. Conclusion {#sec0080}
=============

In conclusion, our findings indicate the potent anti-inflamatory effects of berberine on MCAO model in Wistar rats. Our results show that berberine ameliorates infarct volume, brain edema formation, and contributes to recovery of motor function after focal cerebral ischemia via downregulation of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines.
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